Abstract
Perioperative management of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high thrombotic risk undergoing non-deferrable surgery remains poorly defined. Cangrelor represents a potential bridging treatment option. However, there is limited data in this
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
